搜索
 > 【SLAMF7】重组蛋白信息

SLAMF7信息

英文名称:SLAM family member 7
中文名称:SLAM家族成员-7
靶点别称:CS1,UNQ576/PRO1138,SLAMF7,Novel Ly9,SLAM Family Member 7,Membrane Protein FOAP-12,CD2 Subset 1,Protein 19A,CRACC,CD2-Like Receptor Activating Cytotoxic Cells,CD2-Like Receptor-Activating Cytotoxic Cells,19A24 Protein,CD319,19A,Novel LY9 (Lymphocyte Antige
上市药物数量:1
临床药物数量:4
最高研发阶段:批准上市

SLAMF7 Molecule Synonym Name

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

SLAMF7 分子背景

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7 参考文献

SLAMF7上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Elotuzumab PDL-063; HuLuc-63; BMS-901608 批准上市 艾伯维, 百时美施贵宝 Empliciti Japan 多发性骨髓瘤 Bristol-Myers Squibb Company 2015-11-30 阴燃多发性骨髓瘤, 多发性骨髓瘤 详情

SLAMF7临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
CS1 Targeted CAR T-cells (Yake Biotechnology) 临床一期 Yake Biotechnology Ltd 多发性骨髓瘤 详情
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) 临床阶段不明 武汉波睿达生物科技有限公司, 同济医院 血液肿瘤
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) 临床一期 Icell Gene Therapeutics 多发性骨髓瘤 详情
UCART-CS1 UCART-38; UCART-CS1 临床一期 Cellectis 多发性骨髓瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定